A Multicenter Phase II Study of Combination Treatment with Melphalan, Arsenic Trioxide and Vitamin C (MAC) for Patients with Relapsed or Refractory Multiple Myeloma.

@inproceedings{Berenson2005AMP,
  title={A Multicenter Phase II Study of Combination Treatment with Melphalan, Arsenic Trioxide and Vitamin C (MAC) for Patients with Relapsed or Refractory Multiple Myeloma.},
  author={James R Berenson and Ralph V. Boccia and David Siegel and Marek Bozdech and Alberto Bessudo and Edward A. Stadtmauer and Jeremy Pomeroy and Ronald G. Steis and Marshall S. Flam and Jose Lutzky and Syed Jilani and Joseph Volk and Tiberio Lindgren and Robert A. Moss and Ravi Patel and Delina Ferreti and Howard S. Yeh and Sal Bevivino},
  year={2005}
}
Background: Despite the recent increase in treatment options for patients with multiple myeloma (MM), the disease remains largely incurable. Both arsenic trioxide (ATO) and melphalan have shown clinical activity in MM. Recent in vitro and in vivo studies in our laboratory have shown that arsenic trioxide sensitizes chemoresistant MM cells to melphalan-induced cytotoxicity; the addition of ascorbic acid (AA) further improves this effect. We conducted a multi-center clinical trial to evaluate the… CONTINUE READING

Topics from this paper.

Citations

Publications citing this paper.

The emerging role of novel therapies for the treatment of relapsed myeloma.

  • Journal of the National Comprehensive Cancer Network : JNCCN
  • 2007
VIEW 1 EXCERPT
CITES BACKGROUND